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Abstract
 
Introduction
 
A reliable and valid clinical tool to capture symptoms and signs of diabetic sensorimotor polyneuropathy
(DSP) for use in clinical research trials is urgently needed. The validated Toronto Clinical Neuropathy Score (TCNS) was
modified to improve sensitivity to early DSP changes. We aimed to assess the reproducibility of this modified tool, the
mTCNS and to determine its validity relative to the precursor TCNS.
 
Methods
 
Sixty-five patients (six Type 1, 59 Type 2 diabetes) with diabetes duration 13 
 
±
 
 8 years were accrued from four
study sites and examined on 2 days for internal consistency and inter- and intra-rater reliability of the mTCNS. In the
absence of a single quantitative gold-standard measure for DSP, results of the mTCNS were compared with the precursor
TCNS for the purpose of estimating validity.
 
Results
 
Internal consistency of the two domains within the mTCNS was good (Cronbach’s alpha 0.78). Very good
inter-rater reliability for the mTCNS was demonstrated by an intra-class correlation coefficient for the mTCNS of 0.87
(95% confidence interval, 0.79–0.91), which was similar in magnitude to that of the TCNS (0.83; 95% confidence interval,
0.75–0.89). Intra-rater reliability testing of the mTCNS showed moderate to good correlation for individual symptoms
 
and sensory tests (Cohen’s kappa values of 0.54–0.73). The mTCNS shared moderate correlation with the precursor
TCNS (Pearson correlation coefficient, 0.58).
 
Discussion
 
The mTCNS, a clinical score with higher face validity for tracking mild to moderate DSP, has sufficient
reliability and validity relative to its precursor TCNS for use in clinical research.
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Introduction
 
Although therapeutic agents such as aldose reductase
inhibitors have the potential to restrict the progress of diabetic
sensorimotor polyneuropathy (DSP), none have proven
efficacious [1]. A possible methodological reason is that
clinical assessment of DSP is complex and, as a consequence,
biological improvement in nerve function may not be detectable
owing to the inherent error variability of the clinical research
instruments used to measure DSP. Several instruments
measuring similar clinical features to assess patients with DSP
have been developed for use in research or clinical practice. For
example, the Michigan Neuropathy Screening Instrument (MNSI),
used in the study of the aldose reductase inhibitor zenarestat,
terminated for reasons of toxicity [2], represents the screening
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component of a two-step test requiring ultimate confirmation
of neuropathy by measurement with the Michigan Diabetic
Neuropathy Score (MDNS) [3]. Similarly, a thematically
analogous clinical score, the modified Neuropathy Disability
Score (NDS), has been used in epidemiological studies of DSP
to show association of neuropathy with risk factors [4,5].
Although many other similar scales were concurrently developed
[6–8], the search for a clinical scoring system sensitive to the early
pathophysiological changes of DSP reversible by disease-
modifying therapy such as aldose reductase inhibitors continues.
The Toronto Clinical Neuropathy Score (TCNS; Table 1)
can be used to measure changes in such early DSP pathophy-
siology because of its content validity, and the demonstration
of criterion validity against the morphological criteria of sural
nerve fibre density for DSP [9,10], and of construct validity
against nerve conduction velocities and nerve conduction
amplitudes [10]. The TCNS has been preferred in some clinical
trials owing to its ease of use, acceptability by patients, its
ability to classify the severity of DSP and its representation of
the clinical changes associated with the progression of DSP
[10,11]. Inherent in these attributes, the TCNS has sufficient
reliability and reproducibility as an instrument to document
and monitor DSP in the clinical setting [9].
In a nerve biopsy study of the aldose reductase inhibitor
ranirestat, with a 15-month extension study, the TCNS showed
a statistically significant improvement in the drug-treated
patients compared with baseline assessment [11,12]. In this
study, improvements were observed primarily in the sensory
testing component of the TCNS, but not in the reflex score
component. These results using the TCNS suggested that
ranirestat could reverse aspects of the pathophysiology of DSP
and emphasized the importance of a sensitive clinical scoring
system as the outcome measure in therapeutic trials. The
TCNS was modified (into the mTCNS, shown in Table 2) to
Table 1 The components of the original Toronto Clinical Neuropathy Score (TCNS)
Symptom scores Sensory test scores Reflex scores
Foot pain Pinprick Knee reflexes
Numbness Temperature Ankle reflexes
Tingling Light touch
Weakness Vibration
Ataxia Position sense
Upper limb symptoms
Symptom scores graded as Sensory test scores graded as Reflexes graded as
0 = absent 0 = normal 0 = normal
1 = present 1 = abnormal 1 = reduced
2 = absent
Maximum TCNS is 19 points.
Symptoms and signs (sensory tests) are considered present if because of diabetic sensorimotor polyneuropathy (DSP) in the opinion of the 
investigator. Details of the TCNS have been published previously [9].
Table 2 The components of the modified Toronto Clinical Neuropathy Score (mTCNS)
Symptom scores Sensory test scores
Foot pain Pinprick
Numbness Temperature
Tingling Light touch
Weakness Vibration
Ataxia Position Sense
Upper limb symptoms
Symptom scores graded as Sensory test scores graded as
0 = absent 0 = normal
1 = present but no interference with sense of 
well-being or activities of daily living
1 = reduced at the toes only
2 = reduced to a level above the toes, 
but only up to the ankles
3 = reduced to a level above the ankles 
and/or absent at the toes
2 = present, interferes with sense of well-being but 
not with activities of daily living
3 = present and interferes with both sense of 
well-being and activities of daily living (both)
Maximum mTCNS is 33.
Symptoms and signs (sensory tests) are considered present if as a result of diabetic sensorimotor polyneuropathy (DSP) in the opinion of the 
investigator. 
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better capture a categorical scale of simple sensory tests, which
are better representative of the early dysfunction in DSP, and
to eliminate reflex testing, which represent the late-stage
pathophysiology of DSP, are highly variable between raters
[13], age dependent and heavily weighted in the TCNS [9]. As
such, sensory and symptom levels were introduced in the mTCNS
to improve sensitivity and specificity of the original TCNS.
In view of these potential advantages of the mTCNS over the
TCNS for clinical research involving drugs that could modify
the early pathophysiology of DSP, we aimed to assess the
reproducibility of the mTCNS (measured by inter- and intra-
rater reliability). Secondly, in the absence of a single quantitative
gold-standard measure for DSP, we aimed to simply validate
the mTCNS relative to its precursor, the validated TCNS.
 
Methods
 
We performed a multi-centre study at four centres, three in the
USA and one in Canada (see below for list of study centres). The
local Institutional Review Board at each of the four sites approved
the study protocol prior to enrolment of patients.
 
Patients
 
Sixty-five patients were enrolled (10–22 patients per site). In-
clusion criteria included age 18–70 years, presence of diabetes
mellitus, a sural nerve amplitude response of 1.0 
 
μ
 
V or more
and the presence of symmetrical distal DSP as defined by the
modified San Antonio Criteria, in which two of symptoms,
signs, abnormal nerve conduction parameters or abnormal
vibration perception thresholds (VPT) were required [14].
Patients were stratified for disease severity on the basis of the
TCNS in order to determine the performance of the mTCNS
across the full range of disease severity [9]. Patients were ex-
cluded if they had known non-diabetic causes of neuropathy
(for example, vitamin deficiencies, uraemia, thyroid disease,
lumbar or cervical radiculopathy, inflammatory neuropathy or
presence of alcoholism).
 
Raters
 
Each patient was examined on the same day by 1–3 raters for
inter-rater reliability testing and then tested again within 48 h
by one rater for the intra-observer reliability testing. The raters
were all trained at a single training session before starting the
study in order to standardize the clinical assessments. Ten
raters participated in the study in four study sites.
 
Study procedures
 
At the first visit, demographic information was collected and
the TCNS and mTCNS were performed. Details of the TCNS
have been presented previously [9]. The mTCNS is a brief, easily
administered semi-structured clinical interview and examination
during which the trained raters systematically administered the
11 items that assess symptoms and signs of DSP (see Table 2).
During the pre-study investigator training session, the symptoms
 
of the mTCNS were described and synonyms suggested to
clarify the meaning of the symptoms for patients. Standardized
case report forms contained all the elements of the TCNS and
mTCNS and were used by the study personnel to complete the
scales. The mTCNS rates individual symptoms that are caused
by DSP in the judgment of the examiner as absent or present and,
if present, graded at levels depending on interference with sense
of well-being and/or activities of daily living. Symptoms with-
out interference with sense of well-being or activities of daily
living are graded as 1, those which interfere with sense of well-
being, but not with activities of daily living as 2, or those which
interfere with both as 3. Similarly, each sign as a result of DSP
in the judgment of the examiner is rated as normal (0), abnormal
at toes only (1), between toes and ankle (2) or above ankle (3)
as shown in Table 2.
Other procedures done at the first visit included: MNSI,
MDNS, the NDS, nerve conduction studies (NCS) and quantitative
sensory testing (QST). NCS included motor nerve conduction
studies of the dominant peroneal and tibial and non-dominant
median nerves with corresponding F wave latencies and sensory
nerve conduction studies of bilateral sural, non-dominant median,
radial and ulnar nerves. QST included VPT and cooling detection
thresholds measured using the method of limits and the Medoc
device (Medoc Advanced Medical Systems Ltd, Durham, NC,
USA).
On day 2, each patient had the TCNS and mTCNS performed
by 2–4 raters, including the rater from day 1. The assessments
were performed at least 15 min apart to reduce memory effects.
The time interval of less than 48 h between assessments was
selected to minimize the potential for change in symptoms. All
examinations were masked to the results of all other testing,
including the results of previous TCNS and mTCNS tests. The
TCNS was selected as the criterion standard for DSP in this
study in the absence of a single, universally accepted gold standard
for DSP and the prior demonstration of validity of the TCNS
against the morphological criterion of sural nerve fibre density [10].
The NCS, QST, TCNS and mTCNS were reviewed by a central
Neurological Core Laboratory for quality control according to
established control procedures [15].
To determine the acceptability of the mTCNS to patients, a
cognitive debriefing substudy was conducted in 12 randomly
selected patients (three from each study site) after the completion
of their two study visits. The cognitive debriefing constituted a
qualitative semi-structured one-to-one interview that included
questions pertaining to the importance of each component of
the mTCNS in the opinion of the patients.
 
Statistical methods
 
Internal consistency was assessed for the mTCNS and TCNS
using Cronbach’s alpha [16]. Inter-rater reliability reflects
agreement when the instrument is administered by two or more
different raters. Inter-rater reliability was assessed by the intra-
class correlation coefficient (ICC) and its 95% confidence interval
(CI) from a random effects model in which the patients and
raters (
 
n
 
 
 
=
 
 2–4) were considered random effects. Intra-rater re-
liability reflects the agreement between responses when the
instrument is administered by the same rater on more than one
occasion. It was determined by the Cohen’s kappa statistic 
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[17,18] for the symptom, sensory test and reflex domains of the
mTCNS and TCNS. All raters were combined for calculation of
the Cohen’s kappa. ICC and kappa statistics were interpreted
as very good if 0.81–1.00, good if 0.61–0.80, moderate if 0.41–
0.60, fair if 0.21–0.40 and poor if < 0.20 [19]. Validity of the
mTCNS was simply assessed according to linear correlation
(Pearson coefficients) with the precursor TCNS, but linear
correlations with individual measures of DSP, including the
results of nerve conduction studies and other objective tests,
were calculated.
Construct validity was assessed by correlations of the mTC-
NS with the TCNS, NCS, QST, MDNS and NDS.
 
Results
 
All 65 patients completed the two visits and all study procedures.
Details of their clinical characteristics are shown in Table 3.
The majority of the patients had Type 2 diabetes, mean diabetes
duration of 13.2 years and mean duration of DSP of 6.6 years.
The majority were obese with hypertension. Based on the TCNS,
neuropathy was absent in 12.3%, mild in 21.5%, moderate in
27.7% and severe in 38.5%, although all patients met the San
Antonio Criteria [14] for DSP. As such, those with ‘absent’
neuropathy according to the TCNS had at least mild degrees of
DSP based on the San Antonio criteria.
Ten raters, eight of whom were physicians, participated from
the four centres, with a minimum of two raters per site. Three
of the raters were neurologists or neurophysiologists, one was
an endocrinologist and six had other specialties. The 10 raters
had a mean of approximately 3.5–4 years’ experience with the
TCNS and other similar clinical scoring systems. They had less
experience with the mTCNS (mean 2.6 years). Four (40.0%)
raters indicated that the TCNS was the scale with which they
were most familiar; other scales were most familiar to 1–3
raters each. The raters had a mean of 11.5 years of experience
with neurological examinations and approximately 8 years of
experience with monofilament sensory tests and vibration
perception threshold testing.
 
Internal consistency
 
The components of both the mTCNS and the TCNS showed
good to very good internal consistency. The total scores showed
good internal consistency (Cronbach’s alpha values 0.78 for
the mTCNS and 0.76 for the TCNS). Within the symptom
score and sensory test domains, internal consistency was very
good for the mTCNS (Cronbach’s alpha 0.86 for the symptom
score and 0.80 for the sensory test score). Rather than very
good, the internal consistencies for the equivalent TCNS
domains were good (Cronbach’s alpha 0.64 for the symptom
score and 0.66 for the sensory test score).
 
Inter-rater reliability
 
Inter-rater reliability was very good for the total scores of the
mTCNS and TCNS and comparable in magnitude (Table 4).
The corresponding intra-class correlation coefficients and
95% confidence intervals were 0.87 (0.79–0.91) for the
mTCNS and 0.83 (0.75–0.89) for the TCNS. These statistics
and the intra-class correlation coefficients for the symptom
and sensory test domains are summarized in the first section of
Table 4. In the analysis of the symptom score and sensory test
domains, the sensory test score had moderate agreement for
the mTCNS, but only fair agreement for the TCNS. Measures
of inter-rater reliability tended to have higher correlation for
the mTCNS as compared with the TCNS.
 
Intra-rater reliability
 
Intra-rater reliability was assessed only for individual symptoms
and signs and not the total or domain scores because of the
nature of Cohen’s kappa that is used to analyse discrete
parameters. It uses the counts of cases where there is agreement
between two assessment times. Ninety-nine per cent of paired
values were concordant within a maximum absolute difference
of three points for the mTCNS. For precise concordance of the
exact integer scores, generally Cohen’s kappa values indicated
moderate to very good agreement for the symptoms (Cohen’s
Table 3 Clinical characteristics of the 65 patients with diabetes
Clinical characteristic
Female sex, n (%) 25 (38.5%)
Age (years) 58.5 ± 8.0
Diabetes type
Type 1 diabetes 6 (9.2%)
Type 2 diabetes 59 (90.8%)
Diabetes duration (years) 13.2 ± 8.0
Race
Caucasian 48 (73.8%)
African-American 11 (16.9%)
Asian 3 (4.6%)
Other* 3 (4.6%)
DSP duration (years) 6.6 ± 4.4
TCNS (out of 19 points) 10.4 ± 3.8
Severity of DSP according to the TCNS†
No neuropathy 8 (12.3%)
Mild 14 (21.5%)
Moderate 18 (27.7%)
Severe 25 (38.5%)
mTCNS (out of 33 points) 12.8 ± 6.0
Height (cm) 171.1 ± 9.8
Weight (kg) 103.2 ± 30.9
Body mass index (kg/m2) 35.3 ± 10.2
Systolic blood pressure (mmHg) 134 ± 18
Diastolic blood pressure (mmHg) 77 ± 11
Data are presented as n (%) or means ± SD.
*Other race includes non-Asian, non-Black/African-American 
and non-Caucasian patients.
†Diabetes severity graded according to the results of the TCNS. 
Out of a total score of 19, the grades are defined as follows: 
0–5 = no neuropathy; 6–8 = mild neuropathy; 9–11 = moderate 
neuropathy; ≥ 12 = severe neuropathy.
DSP, diabetic sensorimotor polyneuropathy; SD, standard 
deviation; TCNS, Toronto Clinical Neuropathy Score. 
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kappa values of 0.55–0.73) and sensory tests (Cohen’s kappa
values of 0.54–0.63). Measures of intra-rater reliability were
non-significantly higher for the TCNS as compared with the
mTCNS and are summarized in the second section of Table 4.
The mTCNS demonstrated moderate correlation with the
TCNS (Pearson correlation coefficient of 0.58). Comparison
of the symptom score and sensory test domains showed very
good and good correlation (symptom score Pearson correlation
coefficient, 0.82; sensory test Pearson correlation coefficient,
0.71). Other than the moderate correlation seen between the
mTCNS and the MNSI (Pearson correlation coefficient, 0.63),
in most cases correlation was poor to fair with other clinical
scales. For example, the Pearson correlation coefficient was
0.40 with the MDNS and 0.04 with the NDS. Correlation with
individual quantitative objective tests was also poor. For
example, correlation was 0.13 with VPT and –0.13 with the
summed sensory amplitudes from NCS. However, the Pearson
correlation coefficients with the sensory score domain of the
mTCNS were higher for these parameters—for example,
correlation of this domain with summed sensory amplitude
was –0.45. As such, lower (impaired) sensory amplitudes
correlated with higher sensory test scores.
The results of the cognitive debriefing indicated that most
patients understood the meaning of the questions relating to
DSP symptoms that are part of the mTCNS. In the opinion of
the 12 respondents, they generally reported that the symptoms
in the mTCNS are ‘important’ to ‘very important’ in terms of
their relevance to DSP. Details for each symptom in the mTCNS
scoring system are shown in Table 5.
 
Discussion
 
This study demonstrates that the modification of a well-
validated score, designed to capture the manifestations of the
early processes of DSP better than the precursor score, produces
a measure with similar internal consistency, inter-rater reliability
and intra-rater reliability. The resultant measure, the mTCNS,
maintains acceptable correlation with the precursor score, the
TCNS.
Although this speaks generally to the validity of the mTCNS
simply because the TCNS represents well the morphological
and functional change in peripheral nerves seen in those with
diabetes [9,10], full validation to a quantitative and objective
gold standard measure is challenging owing to the complexity
of the phenotype of DSP. For example, the criterion standard
in clinical research and clinical care for DSP does not consider
abnormality of nerve conduction study parameters to be
diagnostic of DSP unless accompanied by symptoms or signs
[14,20]. Consequently, even our most objective measures for
DSP can be considered insensitive for diagnosis and, by
extension, for change in the early pathophysiological processes
of neuropathy. As such, we did not anticipate strong correlation
between the mTCNS and individual nerve conduction study
parameters or with the results of other individual objective
tests. However, sufficient correlation with the parameters was
observed with the most sensitive objective measures, the
electrophysiological parameters representing sensory nerves.
In particular, the sensory test domain of the mTCNS shares
moderate correlation with the sensory nerve conduction study
parameters and is consistent with earlier reports of construct
validity for the precursor score, the TCNS [10]. In that previous
work, the NCS showed Pearson correlation coefficients in the
range of 0.3–0.5 with the TCNS for summed nerve conduction
velocities, summed amplitudes and sural nerve fibre density
[10]. The difference in correlations with NCS between the
scales is likely as a result of the exclusion of the tendon reflex
scores from the mTCNS, which generally contribute insensi-
tive components for the assessment of early DSP.
Although the mTCNS correlates with the TCNS and other
clinical scales measuring DSP, in many cases the degree of
Table 4 Intra-class correlation coefficients (ICCs) and Cohen’s kappa 
statistics for the evaluation of inter- and intra-rater reliability of the 
mTCNS and TCNS
Parameter mTCNS TCNS
Inter-rater reliability (ICCs)*
Total score 0.87 0.83
Total symptom score 0.92 0.85
Total sensory score 0.52 0.40
Total symptom + sensory score† 0.79
Total reflex score† 0.60
Intra-rater reliability (Cohen’s kappas)‡
Symptoms
Foot pain 0.73 0.75
Numbness 0.57 0.71
Tingling 0.55 0.62
Weakness 0.64 0.74
Ataxia 0.64 0.75
Upper limb symptoms 0.68 0.79
Sensory tests
Pinprick 0.56 0.66
Temperature 0.59 0.62
Light touch 0.59 0.69
Vibration 0.54 1.00
Position sense 0.63 0.69
Reflexes†
Right knee 0.85
Left knee 0.73
Right ankle 0.73
Left ankle 0.76
*All results are based on data from 65 patients evaluated by 
10 raters at visit 2.
†Evaluated only for the TCNS.
‡Cohen’s kappa can only be used to analyse discrete parameters 
because it uses the counts of cases where there is agreement 
between two assessment times. Therefore, analyses were 
based only on individual items of the mTCNS and TCNS, not on 
total scores, which may have had few instances of exact 
agreement because the divisions are too fine. All results are based 
on data from 65 patients each evaluated by the same rater at 
visits 1 and 2 (total of eight raters).
mTCNS, modified Toronto Clinical Neuropathy Score; 
TCNS, Toronto Clinical Neuropathy Score. 
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correlation is lower than would be expected from scales that
make use of similar symptoms and signs. For example, MNSI
shares a Pearson correlation coefficient of 0.63 with the mTCNS,
even although they have in common similar elements on the
semi-structured questionnaire and examination. However,
perfect correlation between the mTCNS and the other clinical
scales (the TCNS, NDS and MNSI) would indicate that the
new modified scale would offer no potential advantage over
the existing metrics for neuropathy. As such, the degree of
correlations observed might indicate advantages of the mTCNS
over the other scales that generally include variables associated
with advanced neuropathy and may therefore be less sensitive
to milder degrees of change in nerve function. Specifically, the
MNSI includes examination of the feet for deformities and
reflexes (not components of the mTCNS), while the NDS
excludes assessment of symptoms in place of reflexes.
Similarly, correlation with specific quantitative sensory tests
(cold detection thresholds) may also relate to the inability of
this test to represent the full DSP phenotype as well as a scale
that includes more sensitive components such as a quantitative
representation of symptoms. Furthermore, cold detection
thresholds are characterized by significant error variability
that may also explain poor correlation with the mTCNS.
The reproducibility of a quantitative measure for DSP is of
fundamental importance as a tool for identifying changes in
DSP severity that are of small magnitude. The very good
inter-rater reliability of the mTCNS in this study (Kraemer’s
kappa 0.87) is comparable with that reported previously from
a study of the TCNS [9]. That the inter-rater reliability is con-
sistent between these two studies is fundamentally important
because the current study is a multi-centre study involving four
different centres and 2–4 different examiners at each site, while
the latter study that established the TCNS as a reproducible
measure was conducted at a single centre [10].
Although serving to quantify the reliability of the mTCNS
and to establish its validity in a patient group with mild to
moderate DSP severity, this analysis has some limitations.
First, the assessment of any proxy score for DSP is hindered by
the lack of a single quantitative gold standard measurement
for neuropathy. As such, the validity of the mTCNS can only
be inferred by its association with the TCNS and components
of objective tests. Second, although performance of the
mTCNS was generalizable among study centres by different
study staff, these centres represent a certain expertise that may
limit our knowledge of the applicability of this test in broader
clinical settings, such as in primary care clinics.
Taken together, the results of this multi-centre study have
implications for future treatment trials in DSP. Patients in this
study were selected for mild to moderate levels of DSP as evidenced
by the presence of bilateral sural nerve responses. This feature
of the study group makes it similar to the patient populations
in prior therapeutic studies of agents such as aldose reductase
inhibitors [11,21]. As clinical studies of such disease-modifying
drugs are expected to be, by necessity, long-term trials [1], highly
reproducible summary scores for DSP are required. The mTCNS
appears to have the necessary reliability measures for inclusion
as an important clinical outcome in these trials.
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Table 5 Cognitive debriefing: modified Toronto Clinical Neuropathy Score (mTCNS) symptom importance to patients with diabetic sensorimotor 
polyneuropathy (DSP)
mTCNS symptom
Important to 
extremely important
Less than 
important Comments
Foot pain 9 (100%) 0 (0%) Even those who reported no foot pain 
still indicated that this symptom was 
‘extremely important’ to them and should 
be asked about by physicians.
Numbness 10 (100%) 0 (0%)
Tingling 9 (90%) 1 (10%) Patients commented that tingling should 
be evaluated relative to numbness.
Weakness 8 (89%) 1 (11%)
Ataxia 7 (78%) 2 (22%) This symptom was commonly confused 
with weakness.
Upper limb symptoms 7 (78%) 2 (22%)
Results given as: number (100%).
Patients were asked: ‘On the following scale, how important is it to you that your diabetes physician asks you about (SYMPTOM)’ where 0 = not 
at all important, 2 = important and 4 = extremely important.
Twelve subjects underwent a 2-h cognitive debriefing session, but not all questions were explored in all patients. 
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mTCNS Study Group and study centres
 
The mTCNS Study Group consists of V. Bril (University of
Toronto, Toronto, Canada), A. Shaibani, S. Schwartz and R.
Weinstein. The four study sites were University Health
Network, Toronto, Canada, Nerve and Muscle Center of
Texas, Houston, Diabetes and Glandular Disease Research
Associates, San Antonio, Texas and Diablo Clinical Research,
Walnut Creek, California, USA.
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